Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- 12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
- FibroGen Shares Positive Results of Phase 2 Trial of Investigational Therapy Pamrevlumab
- Ofev Corrects Blood Vessel Abnormalities Associated with Lung Fibrosis, Study Suggests
- Esbriet, Ofev Safety Profiles in Routine Practice Similar to Clinical Trial Reports, Study Finds
- Esbriet, Ofev Remain Only Effective IPF Therapies Though PRM-151 is Gaining Ground, Comparison Study Finds
- Ofev Could Be Used to Treat Pulmonary Fibrosis Patients’ Lung Cancer, Study Reports
- 37% of Pulmonary Fibrosis Patients Treated with Ofev Maintained Lung Function, Presentation Showed
Esbriet News:
- 12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
- FibroGen Shares Positive Results of Phase 2 Trial of Investigational Therapy Pamrevlumab
- Esbriet, Ofev Safety Profiles in Routine Practice Similar to Clinical Trial Reports, Study Finds
- Some Tips and Resources to Help Tackle Your Sleep Problems
- Esbriet, Ofev Remain Only Effective IPF Therapies Though PRM-151 is Gaining Ground, Comparison Study Finds
- Measures of IPF Therapy Effectiveness Should Include Patients’ Views of Success, Researchers Argue
- European Commission Approves New Esbriet Tablet for IPF Treatment
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
- IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds
- Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
FDA News:
- 4 Common Coughing Triggers for Idiopathic Pulmonary Fibrosis
- FDA Grants Orphan Drug Designation to Samumed’s Investigational SM04646 for IPF Treatment
- 5 Ways Idiopathic Pulmonary Fibrosis Impacts Daily Life
- ProMetic’s Therapy for IPF Receives FDA Approval for More Clinical Trials
- Esbriet and Ofev Improve Pulmonary Fibrosis Lung Function, but Not N-acetylcysteine, Study Suggests
- FDA, at Last, Turns Its Attention to Stem Cell Therapies for PF and Other Chronic Ills
- Pulmonary Fibrosis Treatment with OFEV and Esbriet